Endoscopic Ultrasound Guided Radio Frequency Ablation of Pancreatic Neuroendocrine Neoplasms
A national multicenter prospective study to investigate the feasibility and efficacy of endoscopic ultrasound guided radiofrequency ablation of neuroendocrine pancreatic tumors, WHO Grade 1-2 of 3 cm or less in diameter.
• Age above 18
• EUS fine needle biopsy (FNB) proven pancreatic neuroendocrine tumor (PNET), WHO 2019 Grade 1-2 in patients with functioning or non-functioning tumors. Also
∙ MEN1 patients are eligible:
• PNET 2-3 cm in largest diameter (Based on MRI or CT) with a Ki-67 \<5%, or:
‣ PNET \< 2cm with Ki-67 \<10% that has shown progression during surveillance, or:
⁃ PNET 1.5-2 cm with Ki-67 \<10% in patients age \< 60 years of age, whether progression is detected or not.
• Distance from the main pancreatic duct ≥2 mm, or \<2mm with a prophylactic stent in the main pancreatic duct.
• Patient in good general condition, ECOG performance status 0-2 (see Appendix)
• Signed written informed consent